Key Points
- John Higgins, a director at OmniAb, bought 36,223 shares on Nov. 6 at $1.41 each (≈$51,074), raising his stake to 2,888,110 shares (a 1.27% increase) — the trade was disclosed in an SEC filing.
- OmniAb beat quarterly EPS estimates slightly (reported a ($0.14) loss vs. ($0.15) expected) but missed revenue badly ($2.24M vs. $5.64M expected) and remains unprofitable with negative ROE and a -301.83% net margin.
- The stock opened at $1.49 and was trading up ~8%; the company has a market cap of ~$214.5M, a consensus analyst rating of “Moderate Buy” with an average target of $6.67, and roughly 72% institutional ownership.
OmniAb, Inc. (NASDAQ:OABI - Get Free Report) Director John Higgins bought 36,223 shares of the business's stock in a transaction on Thursday, November 6th. The shares were bought at an average cost of $1.41 per share, for a total transaction of $51,074.43. Following the completion of the acquisition, the director directly owned 2,888,110 shares in the company, valued at approximately $4,072,235.10. This trade represents a 1.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
OmniAb Trading Up 8.0%
Shares of OABI stock opened at $1.49 on Tuesday. OmniAb, Inc. has a 1-year low of $1.22 and a 1-year high of $4.61. The stock has a market cap of $214.50 million, a price-to-earnings ratio of -2.57 and a beta of 0.15. The stock has a 50-day moving average of $1.60 and a 200-day moving average of $1.69.
OmniAb (NASDAQ:OABI - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%.The business had revenue of $2.24 million for the quarter, compared to analysts' expectations of $5.64 million. OmniAb has set its FY 2025 guidance at EPS. Sell-side analysts forecast that OmniAb, Inc. will post -0.61 earnings per share for the current year.
Institutional Investors Weigh In On OmniAb
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. raised its holdings in shares of OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company's stock valued at $25,000 after purchasing an additional 9,716 shares during the period. AQR Capital Management LLC acquired a new position in OmniAb during the 1st quarter worth approximately $25,000. Cerity Partners LLC bought a new position in OmniAb in the first quarter worth approximately $26,000. PNC Financial Services Group Inc. grew its stake in OmniAb by 279.4% in the first quarter. PNC Financial Services Group Inc. now owns 16,276 shares of the company's stock valued at $39,000 after acquiring an additional 11,986 shares during the period. Finally, Corient Private Wealth LLC bought a new stake in shares of OmniAb during the second quarter valued at approximately $53,000. 72.08% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms recently issued reports on OABI. Royal Bank Of Canada dropped their target price on shares of OmniAb from $4.00 to $3.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of OmniAb in a research note on Tuesday, October 14th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, OmniAb has a consensus rating of "Moderate Buy" and an average target price of $6.67.
View Our Latest Analysis on OmniAb
About OmniAb
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
